Immune Checkpoint Inhibition: The Rising Star in Oncology Therapeutics

Immunotherapy has been taking the human oncologic world by storm. In particular, the use of immune checkpoint inhibitors has remarkable potential to provide complete responses. The first USDA conditionally licensed immune checkpoint inhibitor in veterinary medicine, gilvetmab, is now available to oncologists in veterinary medicine, but the primary care veterinarian’s office is where the first all-important conversations about cancer occur. In this session, attendees will become familiar with immune checkpoint inhibitors, learn how they work, how to talk to owners about this therapy, and how patients can benefit.

Not looking for CE credit for this course? You can skip entering your information below and proceed to viewing the webinar here.